Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. develops clinical-stage cancer therapeutics focused on multi-node inhibition of oncogenic pathways. Its lead program, PIKTOR, is an investigational all-oral combination of serabelisib and sapanisertib designed to target PI3K-alpha and dual mTORC1/2 nodes in the PI3K/AKT/mTOR pathway for endometrial and breast cancer. The company also reports on solnerstotug, a V-domain Ig suppressor of T cell activation, or VISTA, inhibitor for advanced solid tumors.
Recurring company news includes oncology trial activity, clinical and regulatory disclosures, operating and financial results, governance updates, capital-structure matters, and Nasdaq inducement equity grants tied to employee compensation.
Sensei Biotherapeutics has released promising data from the Phase 1 dose escalation study of their human monoclonal antibody, SNS-101, targeting the immune checkpoint VISTA. The study shows that SNS-101 is well-tolerated with no dose-limiting toxicities and demonstrates signs of clinical activity, particularly in tumor types typically unresponsive to PD-1 therapies.
Among the 34 patients, promising results were observed in those with microsatellite stable (MSS) endometrial cancer, MSS colorectal cancer, pembrolizumab-resistant renal cell carcinoma, and HPV-positive head and neck cancer.
The pharmacokinetic profile of SNS-101 supports once every three-week dosing, showing linear elimination kinetics and dose-proportional increases in exposure. The ongoing dose expansion portion aims to enroll more patients, with initial data anticipated by the end of 2024.
EGLE Therapeutics announced the appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and John Celebi, as Independent Board Member. Dr. Motlagh's expertise will drive clinical strategy and development, focusing on advancing the company's pipeline in oncology and auto-immunity. Mr. Celebi brings over 25 years of experience in building biotechnology companies. His extensive background includes serving as President and CEO of Sensei Biotherapeutics (NASDAQ: SNSE) and holding leadership positions in various biotech firms.
Sensei Biotherapeutics, Inc. reported financial results for Q1 2024 and recent business highlights, including clinical trial progress, upcoming data presentations, and a strong balance sheet with cash runway into Q4 2025.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.